Header Logo

Connection

Sonal Singh to Risk Assessment

Back to Details
This is a "connection" page, showing publications Sonal Singh has written about Risk Assessment.
Sonal Singh
Connection Strength
1.080
Risk Assessment
  1. Singh S, Stocco G, Theken KN, Dickson A, Feng Q, Karnes JH, Mosley JD, El Rouby N. Pharmacogenomics polygenic risk score: Ready or not for prime time? Clin Transl Sci. 2024 Aug; 17(8):e13893.
    View in: PubMed
    Score: 0.137
  2. Fukunaga MI, Halligan K, Kodela J, Toomey S, Furtado VF, Luckmann R, Han PKJ, Mazor KM, Singh S. Tools to Promote Shared Decision-Making in Lung Cancer Screening Using Low-Dose CT Scanning: A Systematic Review. Chest. 2020 12; 158(6):2646-2657.
    View in: PubMed
    Score: 0.103
  3. Tang W, Chang HY, Zhou M, Singh S. Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis. Sci Rep. 2017 01 20; 7:40120.
    View in: PubMed
    Score: 0.081
  4. Puhan MA, Yu T, Stegeman I, Varadhan R, Singh S, Boyd CM. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. BMC Med. 2015 Oct 01; 13:250.
    View in: PubMed
    Score: 0.074
  5. Singh S, Loke YK, Enright P, Furberg CD. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Postgrad Med J. 2014 Apr; 90(1062):205-7.
    View in: PubMed
    Score: 0.067
  6. Puhan MA, Singh S, Weiss CO, Varadhan R, Boyd CM. A framework for organizing and selecting quantitative approaches for benefit-harm assessment. BMC Med Res Methodol. 2012 Nov 19; 12:173.
    View in: PubMed
    Score: 0.061
  7. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012 Aug 20; 13:138.
    View in: PubMed
    Score: 0.060
  8. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013 Jan; 68(1):114-6.
    View in: PubMed
    Score: 0.059
  9. Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease". Arch Intern Med. 2011 May 23; 171(10):920-2.
    View in: PubMed
    Score: 0.055
  10. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011 Aug; 66(8):699-708.
    View in: PubMed
    Score: 0.055
  11. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009 Feb 09; 169(3):219-29.
    View in: PubMed
    Score: 0.047
  12. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009; 32(3):219-28.
    View in: PubMed
    Score: 0.046
  13. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. BMC Nephrol. 2008 Feb 25; 9:3.
    View in: PubMed
    Score: 0.044
  14. Singh S, Trivedi AN. Spontaneous reports as evidence of adverse drug reactions. South Med J. 2008 Jan; 101(1):16.
    View in: PubMed
    Score: 0.043
  15. Singh S, Shrivastava R, Das V. Formulary conversion programs: the need for patient-specific risk assessment. MedGenMed. 2004 Sep 14; 6(3):28.
    View in: PubMed
    Score: 0.034
  16. Roche M, Nattiv A, Sainani K, Barrack M, Kraus E, Tenforde A, Kussman A, Olson EM, Kim B, Fahy K, Miller E, Diamond E, Meraz S, Singh S, Nattiv A, Fredericson M. Higher Triad Risk Scores Are Associated With Increased Risk for Trabecular-Rich Bone Stress Injuries in Female Runners. Clin J Sport Med. 2023 11 01; 33(6):631-637.
    View in: PubMed
    Score: 0.032
  17. Fain KM, Yu T, Li T, Boyd CM, Singh S, Puhan MA. Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations. J Clin Epidemiol. 2016 06; 74:151-7.
    View in: PubMed
    Score: 0.019
  18. Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):567-75.
    View in: PubMed
    Score: 0.018
  19. Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T, Ramirez J. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. Respir Med. 2014 Nov; 108(11):1569-80.
    View in: PubMed
    Score: 0.017
  20. Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, Varadhan R, Puhan MA. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul; 69(7):616-22.
    View in: PubMed
    Score: 0.016
  21. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost. 2008 Jan; 99(1):38-43.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.